Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Operations of Line II was stopped due to a fire incident earlier
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
_256_384.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Subscribe To Our Newsletter & Stay Updated
